Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alterations but have rarely considered the biological properties of plasma cell-free DNA (cfDNA). We hypothesized that differences in fragment lengths of circulating DNA could be exploited to enhance sensitivity for detecting the presence of ctDNA and for noninvasive genomic analysis of cancer. We surveyed ctDNA fragment sizes in 344 plasma samples from 200 patients with cancer using low-pass whole-genome sequencing (0.4×). To establish the size distribution of mutant ctDNA, tumor-guided personalized deep sequencing was performed in 19 patients. We detected enrichment of ctDNA in fragment sizes between 90 and 150 bp and developed methods for in vitro and in silico size selection of these fragments. Selecting fragments between 90 and 150 bp improved detection of tumor DNA, with more than twofold median enrichment in >95% of cases and more than fourfold enrichment in >10% of cases. Analysis of size-selected cfDNA identified clinically actionable mutations and copy number alterations that were otherwise not detected. Identification of plasma samples from patients with advanced cancer was improved by predictive models integrating fragment length and copy number analysis of cfDNA, with area under the curve (AUC) >0.99 compared to AUC <0.80 without fragmentation features. Increased identification of cfDNA from patients with glioma, renal, and pancreatic cancer was achieved with AUC > 0.91 compared to AUC < 0.5 without fragmentation features. Fragment size analysis and selective sequencing of specific fragment sizes can boost ctDNA detection and could complement or provide an alternative to deeper sequencing of cfDNA.
INTRODUCTION
Blood plasma of patients with cancer contains circulating tumor DNA (ctDNA), but this valuable source of information is diluted by much larger quantities of DNA of noncancerous origins, such that ctDNA usually represents only a small fraction of the total cell-free DNA (cfDNA) (1, 2) . High-depth targeted sequencing of selected genomic regions can be used to detect low amounts of ctDNA, but broader analysis with methods such as whole-exome sequencing (WES) and shallow whole-genome sequencing (sWGS) is only generally informative when ctDNA content is ~10% or greater (3) (4) (5) . The concentration of ctDNA can exceed 10% of the total cfDNA in patients with advanced-stage cancers (6) (7) (8) , but is much lower in patients with low tumor burden (9) (10) (11) (12) and in patients with some cancer types such as gliomas and renal cancers (6) . Current strategies to improve ctDNA detection rely on increasing depth of sequencing coupled with various error correction methods (2, 13, 14) . However, approaches that focus only on genomic alterations do not take advantage of the potential differences in chromatin organization or fragment sizes of ctDNA (15) (16) (17) . Results of ever-deeper sequencing are also confounded by the likelihood of false-positive results from detection of mutations from noncancerous cells, clonal expansions in normal epithelia, or clonal hematopoiesis of indeterminate potential (CHIP) (13, 18, 19) .
The cell of origin and the mechanism of cfDNA release into blood can mark cfDNA with specific fragmentation signatures, potentially providing precise information about cell type, gene expression, cell physiology or pathology, or action of treatment (15, 16, 20) . cfDNA fragments commonly show a prominent mode at 167 bp, suggesting release from apoptotic caspase-dependent cleavage (Fig. 1A) (21) (22) (23) (24) . Circulating fetal DNA has been shown to be shorter than maternal DNA in plasma, and these size differences have been used to improve sensitivity of noninvasive prenatal diagnosis (22, (25) (26) (27) . The size distribution of tumor-derived cfDNA has only been investigated in a few studies, encompassing a small number of cancer types and patients, and showed conflicting results (28) (29) (30) (31) (32) (33) . A limitation of previous studies is that determining the specific sizes of tumor-derived DNA fragments requires detailed characterization of matched tumorderived alterations (30, 33) , and the broader understanding and implications of potential biological differences have not previously been explored.
We hypothesized that we could improve the sensitivity for noninvasive cancer genomics by selective sequencing of ctDNA fragments and by leveraging differences in the biology that determine DNA fragmentation. To test this, we established a pan-cancer catalog of cfDNA fragmentation features in plasma samples from patients with different cancer types and healthy individuals to identify biological features enriched in tumor-derived DNA. We developed methods for selecting specific sizes of cfDNA fragments before sequencing and investigated the impact of combining cfDNA size selection with genome-wide sequencing to improve the detection of ctDNA and the identification of clinically actionable genomic alterations.
RESULTS

Surveying the fragmentation features of tumor cfDNA
We generated a catalog of cfDNA fragmentation features (Fig. 1A ) in 344 plasma samples from 200 patients with 18 different cancer types and additional 65 plasma samples from healthy controls (Fig. 1B,  fig. S1 , and tables S1 and S2). The size distribution of cfDNA fragments in patients with cancer differed in the size ranges of 90 to 150 bp, 180 to 220 bp, and 250 to 320 bp compared to healthy individuals ( Fig. 1B and fig. S2 ). cfDNA fragment sizes in plasma of healthy individuals and in plasma of patients with late-stage glioma, renal, pancreatic, and bladder cancers were significantly longer than in other late-stage cancer types including breast, ovarian, lung, melanoma, colorectal, and cholangiocarcinoma (Kruskal-Wallis, P < 0.001; Fig. 1C ). Sorting the 18 cancer types according to the proportion of cfDNA fragments in the size range of 20 to 150 bp resulted in an order very similar to that obtained by Bettegowda et al. (6) based on the concentrations of ctDNA measured by individual mutation assays (Fig. 1D) . In contrast to previous reports (6, 34) , this sorting was performed without any analysis or prior knowledge of the presence of mutations or somatic copy number alterations (SCNAs) yet allowed the investigation of ctDNA content in different cancers.
Sizing up mutant ctDNA
We determined the size profile of mutant ctDNA in plasma using two high-specificity approaches. First, we inferred the specific size profile of ctDNA and nontumor cfDNA with sWGS from the plasma of mice bearing human ovarian cancer xenografts ( Fig. 2A) . We observed a shift in ctDNA fragment sizes to less than 167 bp (Fig. 2B) . Second, the size profile of mutant ctDNA was determined in plasma from 19 patients with cancer, using deep sequencing with patientspecific hybrid-capture panels developed from whole-exome profiling of matched tumor samples (Fig. 2C) . By sequencing hundreds of mutations at a depth of >300× in cfDNA, we obtained allelespecific reads from mutant and normal DNA. Enrichment of DNA fragments carrying tumor-mutated alleles was observed in fragments between ~20 and 40 bp shorter than nucleosomal DNA sizes (multiples of 167 bp; Fig. 2D ). We determined that mutant ctDNA is generally more fragmented than nonmutant cfDNA, with a maximum enrichment of ctDNA in fragments between 90 and 150 bp ( fig. S3) , as well as enrichment in the size range of 250 to 320 bp. These data also indicated that mutant DNA in plasma of patients with advanced cancer (before treatment) is consistently shorter than predicted mononuclesomal and dinucleosomal DNA fragment lengths (Fig. 2D) .
Selecting tumor-derived DNA fragments
We evaluated whether the shorter cfDNA fragments in plasma can be harnessed to improve ctDNA detection. We determined the feasibility of selective sequencing of shorter fragments using in vitro size selection with a bench-top microfluidic device followed by sWGS in 48 plasma samples from 35 patients with high-grade serous ovarian cancer (HGSOC; Fig. 3A and figs. S4 and S5). We assessed the accuracy and quality of the size selection with the plasma from 20 healthy individuals ( Fig. 3B and fig. S6 ). We also explored the utility of in silico size selection of fragmented DNA using read-pair positioning from unprocessed sWGS data (Fig. 3A) . In silico size selection was performed once reads were aligned to the genome reference, by selecting the paired-end reads that corresponded to the fragment lengths in a 90-to 150-bp size range. Figure 3 (C to E) shows the effect of in vitro size selection for one HGSOC case (see all five samples in figs. S7 and S8). First, we identified SCNAs in plasma cfDNA before treatment, when the concentration of ctDNA was high (Fig. 3C) . Only a small number of focal SCNAs were observed in the subsequent plasma sample collected 3 weeks after initiation of chemotherapy (without size selection; Fig. 3D ). In vitro size selection of the same posttreatment plasma sample showed a median increase of 6.4× in the amplitude of detectable SCNAs without size selection. Selective sequencing of shorter fragments in this sample resulted in the detection of multiple other SCNAs that were not observed without size selection (Fig. 3E ) and a genome-wide copy number profile that was similar to that obtained before treatment when ctDNA concentrations were four times higher, with additional copy number alterations identified in this sample despite the lower initial concentration of ctDNA (Fig. 3C) . In silico size selection also enriched ctDNA but to a lower extent than using in vitro size selection ( fig. S7 ). We concluded that selecting short DNA fragments in plasma can enrich tumor content on a genome-wide scale.
Quantifying the impact of size selection
To quantitatively assess the enrichment after size selection on a genome-wide scale, we developed a metric from sWGS data (<0.4× coverage) called t-MAD (trimmed median absolute deviation from copy number neutrality; see Fig. 4A ). All sWGS data were down sampled to 10 million sequencing reads for comparison. To define the detection threshold, we measured the t-MAD score for sWGS data from 65 plasma samples from 46 healthy individuals and took the maximal value (median, 0.01; range, 0.004 to 0.015). We compared t-MAD to the mutant allele fraction (MAF) in high ctDNA cancer types as assessed by digital polymerase chain reaction (dPCR) 3 of 13 or WES in 97 samples. We observed a high correlation (Pearson correlation, r = 0.80) between t-MAD and MAF (Fig. 4B) for samples with t-MAD greater than the detection threshold (0.015) or with MAF > 0.025. Figure S9 shows that the slope of t-MAD versus MAF fit lines differed between cancer types (range, 0.17 to 1.12), likely reflecting differences in the extent of SCNAs. We estimated the (6), with orange representing samples from patients with cancer types previously observed to have low amounts of ctDNA (renal, bladder, pancreatic, and glioma) and blue representing samples from patients with cancer types previously observed to have higher amounts of ctDNA (breast, melanoma, ovarian, lung, colorectal, cholangiocarcinoma, and others; see table S1). (C) Proportion of cfDNA fragments below 150 bp in those samples, grouped into cancer types as defined in (B). The Kruskal-Wallis (KW) test for difference in size distributions indicated a significant difference between the group of samples from cancer types releasing high amounts of ctDNA and the group of samples from cancer types releasing low amounts, as well as the group of samples from healthy individuals). (D) Proportion of cfDNA fragments below 150 bp by cancer type (all samples). Cancer types represented by fewer than four individuals are grouped in the "other" category. Red lines indicate the median proportion for each cancer type. ChC, cholangiocarcinoma. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. sensitivity of t-MAD for detecting low amounts of ctDNA using a spike-in dilution of DNA from a patient with a TP53 mutation into DNA from a pool of seven healthy individuals ( fig. S10 ), which confirmed that the t-MAD score was linear with ctDNA fraction down to MAF of ~0.01. In addition, t-MAD scores greater than the detection threshold (0.015) for samples were present even in samples with MAF as low as 0.004. t-MAD was also strongly correlated with tumor volume determined by RECIST1.1 (Pearson correlation, r = 0.6; P < 0.0001; n = 35; fig. S11 ).
Using t-MAD, we detected ctDNA from 69% (130 of 189) of the samples from cancer types where ctDNA concentrations were shown to be high (Fig. 4C ). From cancer types for which ctDNA concentrations are suspected to be low (glioma, renal, bladder, and pancreatic), we detected ctDNA in 17% (10 of 57) of the cases (Fig. 4C) . We used in silico size selection of the DNA fragments between 90 and 150 bp from the high ctDNA cancers (n = 189) and healthy controls (n = 65) to improve the sensitivity for detecting t-MAD (Fig. 4D ). Receiver operating characteristic (ROC) analysis comparing the t-MAD score for the samples revealed an area under the curve (AUC) of 0.90 after in silico size selection, against an AUC of 0.69 without size selection (Fig. 4D) .
We explored whether size-selected sequencing could improve the detection of response or disease progression. We used sWGS of longitudinal plasma samples from six patients with cancer (Fig. 4 , E and F) and in silico size selection of the cfDNA fragments between 90 and 150 bp. In two patients, size-selected samples indicated tumor progression 60 and 87 days before detection by imaging or unselected t-MAD analysis (Fig. 4 , E and F). Other longitudinal samples exhibited improvements in the detection of ctDNA with t-MAD and size selection (Fig. 4F ).
Identifying more clinically relevant genomic alterations with size selection
We next tested whether size selection could increase the sensitivity for detecting cancer genomic alterations in cfDNA. To test effects on copy number aberrations, we studied 35 patients with HGSOC as the archetypal copy number-driven cancer (35) . t-MAD was used to quantify the enrichment of ctDNA with in vitro size selection in 48 plasma samples, including samples collected before and after initiation of chemotherapy treatment. In vitro size selection resulted in an increase in the calculated t-MAD score from the sWGS data for 47 of 48 of the plasma samples (98%; t test, P = 0.06) with a mean of 2.5 and median of 2.1-fold increase ( Fig. 5A and table S3 ). We compared the t-MAD scores against those obtained by sWGS for the plasma samples from healthy individuals. Thirty-nine of the 48 size-selected HGSOC plasma samples (82%) had a t-MAD score greater than the highest t-MAD value determined in the in vitro size-selected healthy plasma samples ( Fig. 5A and figs. S6 and S12), compared to 24 of 48 without size selection (50%). ROC analysis comparing the t-MAD score for the samples from patients with cancer (pre-and posttreatment initiation, n = 48) and healthy controls (n = 46) revealed an AUC of 0.97 after in vitro size selection, with maximal sensitivity and specificity of 90 and 98%, respectively. This was superior to detection by sWGS without size selection (AUC, 0.64; Fig. 5B ). We then determined whether this improved sensitivity resulted in the detection of SCNAs with potential clinical value. Across the genome, t-MAD scores evaluating SCNAs were higher after size selection in 33 of 35 (94%) patients with HGSOC, and the magnitude of copy number (log 2 ratio) values significantly increased after in vitro size selection (t test for the means, P = 0.003; Fig. 5C ). We compared the relative copy number values for 15 genes frequently altered in HGSOC (table S4) . Analysis of plasma cfDNA after size selection revealed a large number of SCNAs that were not observed in the same samples without size selection (Fig. 5D ), including amplifications in key genes such as NF1, TERT, and MYC ( fig. S13 ).
We also tested whether similar enrichment was seen for substitutions to exclude the possibility that size selection might only increase the sensitivity for sWGS analysis. We performed WES of plasma cfDNA from 23 patients with seven cancer types ( fig. S1 ). We used the WES data to compare the size distributions of fragments carrying mutant or nonmutant alleles (Fig. 6A) and to test whether size selection could identify additional mutations. We first selected six patients with HGSOC and performed WES of plasma DNA with and without in vitro size selection in the range of 90 to 150 bp, analyzing time points before and after initiation of treatment (36) . In addition, in silico size selection for the same range of fragment sizes was performed (Fig. 6A) . Analysis of the MAF of SNVs revealed statistically significant enrichment of the tumor fraction with both in vitro size selection (mean, 4.19-fold; median, 4.27-fold increase; t test, P < 0.001) and in silico size selection (mean, 2.20-fold; median, 2.25-fold increase; t test, P < 0.001; Fig. 6A and fig. S14 ). Three weeks after initiation of treatment, ctDNA fractions are often lower (36) , and therefore, we further analyzed posttreatment plasma samples using TAm-Seq (37) . We observed enrichment of MAFs by in vitro size selection between 0.9 and 11 times (mean, 2.1 times; median, 1.5 times), with one outlier sample exhibiting a relative enrichment of 118 times compared to the same samples without size selection ( fig. S15) . Size selection with both in vitro and in silico methods increased the number of mutations detected by WES by an average of 53% compared to no size selection (Fig. 6B) . We identified a total of 1023 mutations in the samples without size selection. An additional 260 mutations were detected by in vitro size selection, and an additional 310 mutations were called after in silico size selection (Fig. 6B  and table S5 ). To exclude the possibility that the improved sensitivity for mutation detection was a result of sequencing artifacts, we validated whether new mutations were also detectable in tumor specimens. We used in silico size selection in an independent cohort of 16 patients for whom matched tumor tissue DNA was available (table S6). In silico size selection enriched the MAF for nearly all mutations (2061 of 2133, 97%), with an average increase of MAF of 1.7× (Fig. 6C ). For 13 of 16 patients (81%), we identified additional mutations in plasma after in silico size selection. Of these 82 additional mutations, 23 (28%) were confirmed to be present in the matched tumor tissue DNA (Fig. 6D) . This included mutations in key cancer genes including BRAF, ARID1A, and NF1 ( fig. S16 ).
Detecting cancer by supervised machine learning combining cfDNA fragmentation and somatic alteration analysis Although in vitro and in silico size selection increase the sensitivity of detection, they also result in a loss of cfDNA for analysis. In analysis of ctDNA based on genomic signals, potentially informative data are lost because regions of the cancer genome that are not mutated or altered do not contribute to detection ( fig. S17 ). We hypothesized that leveraging other biological properties of the cfDNA fragmentation profile could enhance the detection of ctDNA.
We defined other cfDNA fragmentation features from sWGS data including (i) the proportion of fragments in multiple size ranges, (ii) the ratios of proportions of fragments in different sizes, and (iii) the amplitude of oscillations in fragment size density with 10-bp periodicity (see Materials and Methods and Fig. 7A ). These fragmentation features were compared between patients with cancer and healthy individuals ( fig. S18 ), Comparison of t-MAD scores determined from sWGS between healthy samples and samples collected from patients with cancer types that exhibit low amounts of ctDNA and from patients with cancer types that exhibit high amounts of ctDNA (as in Fig. 1 ). All samples for which t-MAD could be calculated have been included. (D) ROC analysis comparing the classification of these plasma samples from high ctDNA cancer samples (n = 189) and plasma samples from healthy controls (n = 65) using t-MAD had an AUC of 0.69 without size selection (black solid curve). After applying in silico size selection to the samples from patients with cancer, we observed an AUC of 0.90 (black dashed curve). (E) Determination of t-MAD from longitudinal plasma samples of a patient with colorectal cancer. t-MAD was analyzed before and after in silico size selection of the DNA fragments between 90 and 150 bp and then compared to the RECIST status for this patient. PR, partial response; SD, stable disease; PD, progressive disease. (F) Application of in silico size selection to six patients with long-term follow-up. t-MAD score was determined before and after in silico size selection of the short DNA fragments. Dark blue circles indicate samples in which ctDNA was detected both with and without in silico size selection. Light blue circles indicate samples where ctDNA was detected only after in silico size selection. Open circles indicate samples where ctDNA was not detected by either analysis. Times when RECIST status was assessed are indicated by a red bar for progression or an orange bar for regression or stable disease. PC, prostate cancer; CRC, colorectal cancer; ChC, cholangiocarcinoma; BC, breast cancer. The numbers correspond to the patients. and the feature representing the proportion (P) of fragments between 20 and 150 bp exhibited the highest AUC (0.819). Principal components analysis (PCA) of the samples represented by t-MAD and fragmentation features showed a separation between healthy samples and samples from patients with cancer and identified fragment features that were aligned (in PCA) with t-MAD scores (Fig. 7B) .
We next explored the potential of fragmentation features to enhance the detection of tumor DNA in plasma samples. A predictive analysis was performed using the t-MAD score and nine fragmentation features across 304 samples (239 from patients with cancer and 65 from healthy controls; Fig. 7C, fig. S19 , and table S2). The nine fragmentation features determined from sWGS included five features based on the proportion (P) of fragments in defined size ranges: P(20 to 150), P(100 to 150), P(160 to 180), P(180 to 220), and P(250 to 320); three features based on ratios of those proportions: P(20 to 150)/P(160 to 180), P(100 to 150)/P(163 to 169), and P(20 to 150)/P(180 to 220); and a further feature based on the amplitude of the oscillations having 10-bp periodicity observed below 150 bp.
Variable selection and the classification of samples as "healthy" or "cancer" were performed using logistic regression (LR) and random forest (RF) models trained on 153 samples and validated on two datasets of 94 and 83 independent samples (Fig. 7C) . The best feature set for the LR model included t-MAD, 10-bp amplitude, P(160 to 180), P(180 to 220), and P(250 to 320). The same five variables were independently identified using the RF model (with some differences in their ranking). Figure S20 shows performance metrics for the different algorithms on training set data using cross-validation. Using t-MAD alone in the validation pan-cancer dataset ( Fig. 7D and fig. S19 ), we could distinguish cancer samples from healthy individuals with an AUC of 0.764. Using the LR model improved the classification of the samples to an AUC of 0.908. The RF model (trained on the 153-sample training set) could distinguish cancer from healthy individuals even more accurately in the validation dataset (n = 94) with an AUC of 0.994. On the second validation dataset containing low-ctDNA cancer samples (n = 83; Fig. 7E ), t-MAD alone or the LR performed less well, with AUC values of 0.421 and 0.532, respectively. However, the RF model was still able to distinguish low-ctDNA cancer samples from healthy controls with an AUC of 0.914. At a specificity of 95%, the RF model correctly classified as cancer in 64 of 68 (94%) of the samples from high-ctDNA cancers (colorectal, cholangiocarcinoma, ovarian, breast, and melanoma) and 37 of 57 (65%) of the samples from low-ctDNA cancers (pancreatic, renal, and glioma; Fig. 7F ). In a second iteration of model training, we omitted t-MAD using only the four fragmentation features (fig. S21 ). The RF model could still distinguish cancer from healthy controls, albeit with slightly reduced AUCs (0.989 for cancer types with high amounts of ctDNA and 0.891 for cancer types with low amounts of ctDNA), suggesting that the cfDNA fragmentation pattern is the most important predictive component.
DISCUSSION
Our results indicate that exploiting fundamental properties of cfDNA with fragment-specific analyses can allow more sensitive evaluation of ctDNA. We based the fragment size selection criteria on a biological observation that ctDNA fragment size distribution is shifted from noncancerous cfDNA. Our work builds on a comprehensive survey of plasma cfDNA fragmentation patterns across 200 patients with multiple cancer types and 65 healthy individuals. We identified features that could determine the presence and amount of ctDNA in plasma samples, without a priori knowledge of somatic aberrations. We caution that this catalog is limited to double-stranded DNA from plasma samples and is subject to potential biases incurred by the DNA extraction and sequencing methods we used. Additional biological effects could contribute to further selective analysis of cfDNA. Other bodily fluids (urine, cerebrospinal fluid, and saliva), different nucleic acids and structures, altered mechanisms of release into circulation, or sample processing methods could exhibit varying fragment size signatures and could offer additional exploitable bio logical patterns for selective sequencing.
Previous work has reported the size distributions of mutant ctDNA but only considered limited genomic loci, cancer types, or cases (30, 32, 33) . We identified the size differences between mutant and nonmutant DNA on a genome-wide and pan-cancer scale. We developed a method to size mutant ctDNA without using high-depth WGS. By sequencing >150 mutations per patient at high depth, we obtained large numbers of reads that could be unequivocally identified as tumor derived and thus determined the size distribution of mutant ctDNA and nonmutant cfDNA in patients with cancer. A potential limitation of our approach is that capture-based sequencing is biased by probe capture efficiency and, therefore, our data may not accurately reflect ctDNA fragments of <100 or >300 bp.
Our work provides strong evidence that the modal size of ctDNA for many cancer types is less than 167 bp, which is the length of DNA wrapped around the chromatosome. In addition, our work also shows that there is enrichment of mutant DNA fragments at sizes greater than 167 bp, notably in the range of 250 to 320 bp. These longer fragments may explain previous observations that longer ctDNA can be detected in the plasma of patients with cancer (29, 32) . The origin of these long fragments is still unknown, and their observation could be linked to technical factors. However, it is likely that mechanisms of compaction and release of cfDNA into circulation, which may differ depending on its origin, will be reflected by different fragment sizes (38) . Improving the characterization of these fragments will be important, especially for future work combining analysis of ctDNA with that of other entities in blood such as microvesicles and tumor-educated platelets (39, 40) . Fragment-specific analyses not only increase the sensitivity for detection of rare mutations but could also be used to track modifications in the size distribution of ctDNA. Future work should address whether this approach could be used to elucidate mechanistic effects of treatment on tumor cells, for example, by distinguishing between necrosis and apoptosis based on fragment size (41) .
Genome-wide and exome sequencing of plasma DNA at multiple time points during cancer treatment have been proposed as noninvasive means to study cancer evolution and for the identification of possible mechanisms of resistance to treatment (3). However, WGS and WES For each sample, fragmentation features included the proportion (P) of fragments in specific size ranges, the ratio between certain ranges, and a quantification of the amplitude of the 10-bp oscillations in the 90-to 145-bp size range calculated from the periodic "peaks" and "valleys." (B) PCA comparing cancer and healthy samples using data from t-MAD scores and the fragmentation features. Red arrows indicate features that were selected as informative by the predictive analysis. (C) Workflow for the predictive analysis combining SCNAs and fragment size features. sWGS data from 182 plasma samples from patients with cancer types with high amounts of ctDNA (colorectal, cholangiocarcinoma, lung, ovarian, and breast) were split into a training set (60% of samples) and a validation set (validation data 1, together with the healthy individual validation set). A further dataset of sWGS from 57 samples of cancer types exhibiting low amounts of ctDNA (glioma, renal, and pancreatic) was used as validation data 2, together with the healthy individual validation set. Plasma DNA sWGS data from healthy controls were split into a training set (60% of samples) and a validation set (used in both validation data 1 and validation data 2). (D) ROC curves for validation data 1 (samples from patients with cancer with high ctDNA amounts, 68; healthy, 26) for three predictive models built on the pan-cancer training cohort (cancer, 114; healthy, 39). The beige curve represents the ROC curve for classification with t-MAD only, the long-dashed green line represents the LR model combining the top five features based on recursive feature elimination [t-MAD score, 10-bp amplitude, P(160 to 180), P(180 to 220), and P(250 to 320)], and the red dashed line shows the result for a RF classifier trained on the combination of the same five features, independently chosen for the best RF predictive model. FF, fragment size features. (E) ROC curves for validation data 2 (samples from patients with cancer with low ctDNA amounts, 57; healthy, 26) for the same three classifiers as in (D). The beige curve represents the model using t-MAD only, the long-dashed green curve represents the LR model combining the top five features [t-MAD score, 10-bp amplitude, P(160 to 180), P(180 to 220), and P(250 to 320)], and the red dashed curve shows the result for a RF classifier trained on the combination of same five predictive features. (F) Plot representing the probability of classification as cancer with the RF model for all samples in both validation datasets. Samples are separated by cancer type and sorted within each by the RF probability of classification as cancer. The horizontal dashed line indicates 50% probability (achieving specificity of 24 of 26, 92.3%), and the long-dashed line indicates 33% probability (achieving specificity of 22 of 26, 84.6%).
approaches are costly and have thus far been applicable only in samples for which the tumor DNA fraction was >5 to 10% (3) (4) (5) 42) . We demonstrated that we could exploit the differences in fragment lengths using in vitro and in silico size selection to enrich for tumor content in plasma samples, which improved mutation and SCNA detection in sWGS and WES data. We demonstrated that size selection improved the detection of mutations that are present in plasma at low allelic fractions while maintaining low sequencing depth by sWGS and WES. Size selection can be achieved with simple means and at low cost and is compatible with a wide range of downstream genomewide and targeted genomic analyses, greatly increasing the potential value and utility of liquid biopsies as well as the cost-effectiveness of cfDNA sequencing.
Size selection can be applied in silico, which incurs no added costs, or in vitro, which adds a simple and low-cost intermediate step that can be applied to either the extracted DNA or the libraries created from it. This approach, applied prospectively to new studies, could boost the clinical utility of ctDNA detection and analysis and creates an opportunity for reanalysis of large volumes of existing data (4, 34, 43) . The limitation of this technique is a potential loss of material and information, because some of the informative fragments may be found in size ranges that are filtered out or deprioritized in the analysis. This may be particularly problematic if only a few copies of the fragments of interest are present in the plasma. Despite potential loss of material, we demonstrated that classification algorithms can learn from cfDNA fragmentation features and SCNA analysis and improve the detection of ctDNA with a cheap sequencing approach. Moreover, the cfDNA fragmentation features alone can be leveraged to classify cancer and healthy samples with a high accuracy [AUC, 0.989 (high ctDNA cancers) and 0.891 (low ctDNA cancers)].
Analysis of fragment sizes could provide improvements in other applications. Introducing fragment size information on each read could enhance mutation-calling algorithms from high-depth sequencing to distinguish tumor-derived mutations from other sources such as somatic variants or background sequencing noise. In addition, cfDNA from patients analyzed with CHIP is likely to be structurally different from ctDNA released during tumor cell proliferation (18, 19) . Thus, fragmentation analysis or selective sequencing strategies could be applied to distinguish clinically relevant tumor mutations from those present in clonal expansions of normal cells. This will be critical for the development of cfDNA-based methods for identification of patients with early-stage cancer.
Size selection could also have an impact on the detection of other types of DNA in body fluids or enrichment of signals from circulating bacterial or pathogen DNA and mitochondrial DNA. These DNA fragments are not associated with nucleosomes and are often highly fragmented below 100 bp. Filtering or selection of such fragments may prove to be important in light of the recently established link between the microbiome and treatment efficiency (17, 44) . Moreover, recent work highlights a stronger correlation of ctDNA detection with cellular proliferation than with cell death (45) . We hypothesize that the mode of the distribution of ctDNA fragment sizes at 145 bp could reflect cfDNA released during cell proliferation, and the fragments at 167 bp may reflect cfDNA released by apoptosis or maturation/ turnover of blood cells. The effect of other cancer hallmarks (46) on ctDNA biology, structure, concentration, and release is yet unknown.
In summary, ctDNA fragment size analysis, via size selection and machine learning approaches, boosts noninvasive genomic analysis of tumor DNA. Size selection of shorter plasma DNA fragments enriches ctDNA and assists in the identification of a greater number of genomic alterations with both targeted and untargeted sequencing at minimal additional cost. Combining cfDNA fragment size analysis and the detection of SCNAs with a nonlinear classification algorithm improved the discrimination between samples from patients with cancer and those from healthy individuals. Because the analysis of fragment sizes is based on the structural properties of ctDNA, size selection could be used with any downstream sequencing applications. Our work could help overcome current limitations of sensitivity for liquid biopsy, supporting expanded clinical and research applications. Our results indicate that exploiting the endogenous biological properties of cfDNA provides an alternative paradigm to deeper sequencing of ctDNA.
MATERIALS AND METHODS
Study design
Three hundred forty-four plasma samples from 200 patients with multiple cancer types were collected along with plasma from 65 healthy controls. Among the patients, 172 individuals, and notably the OV04 samples, were recruited through prospective clinical studies at Addenbrooke's Hospital, Cambridge, UK, approved by the local research ethics committee (REC reference number: 07/Q0106/63; and National Research Ethics Service Committee East of England-Cambridge Central 03/018). Written informed consent was obtained from all patients, and blood samples were collected before and after initiation of treatment with surgery or chemotherapeutic agents. DNA was extracted from 2 ml of plasma using the QIAamp Circulating Nucleic Acid Kit (QIAGEN) or QIAsymphony (QIAGEN) according to the manufacturer's instructions. In addition, 28 patients were recruited as part of the Copenhagen Prospective Personalized Oncology (CoPPO) program (PMID reference number: 25046202) at Rigshospitalet, Copenhagen, Denmark, approved by the local research ethics committee. Baseline tumor tissue biopsies were available from all 28 patients, together with rebiopsies collected at relapse from two patients, and matched plasma samples. Brain tumor patients were recruited at Addenbrooke's Hospital, Cambridge, UK as part of the BLING (bopsies of liquids in new gliomas) study (REC reference number: 15/EE/0094). Patients with bladder cancer were recruited at the Netherlands Cancer Institute, Amsterdam, The Netherlands, and approval according to national guidelines was obtained (N13KCM/CFMPB250) (47) . Sixty-five plasma samples were obtained from healthy control individuals using a similar collection protocol (Seralab). Plasma samples have not been freeze thawed more than two times to reduce artifactual fragmentation of cfDNA. A flowchart of the study is presented in fig. S1 .
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